SCHEMBL722336

SCHEMBL722336

O=C(O)Cc1ccc(Cl)cc1C(F)(F)F

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLQ O75417 2/20 0.62
P2RX7 Q99572 2/20 0.46
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
RXRA P19793 3/20 0.46
RXRB P28702 3/20 0.46
RXRG P48443 3/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
RAB9A P51151 1/20 0.45
PTGS2 P35354 1/20 0.45
CXCL8 P10145 1/20 0.43
CYP2C9 P11712 1/20 0.43
CHRM1 P11229 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.43
PTGDR2 Q9Y5Y4 2/20 0.42
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL194988 0.92 POLQ (0.55) POLQP2RX7KEAP1NFE2L2RXRA
SCHEMBL671103 0.86 POLQ (0.48) POLQP2RX7KEAP1NFE2L2RXRA
SCHEMBL15532382 0.83 POLQ (0.52) POLQRXRARXRBRXRGCYP1A2
SCHEMBL27818434 0.82 POLQ (0.51) POLQCYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL15897802 0.81 POLQ (0.56) POLQP2RX7CYP1A2CYP2D6CYP2C19
SCHEMBL892786 0.81 IDO1 (0.53) POLQP2RX7RXRARXRBRXRG
SCHEMBL30716953 0.81 POLQ (0.61) POLQRXRARXRBRXRGPTGDR2
SCHEMBL3741058 0.81 POLQ (0.61) POLQRXRARXRBRXRGPTGDR2
SCHEMBL14793818 0.81 CAMK2A (0.47) POLQRXRARXRBRXRGPTGS2
SCHEMBL12682526 0.80 POLQ (0.50) POLQP2RX7CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702396-B2 Hydrophobic compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-07-18 US disclosed
EP-3728339-B1 COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS AMO Ireland (IE) 2022-07-06 EP disclosed
US-11359031-B2 Composition for ophthalmological products Johnson & Johnson Surgical Vision, Inc. (US) 2022-06-14 US disclosed
US-20210363122-A1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2021-11-25 US disclosed
US-11078177-B2 Compounds for optically active devices MERCK PATENT GMBH (DE) 2021-08-03 US disclosed
US-11040990-B2 Compounds containing Si atoms for optically active devices MERCK PATENT GMBH (DE) 2021-06-22 US disclosed
US-11001576-B2 Compounds for optically active devices MERCK PATENT GMBH (DE) 2021-05-11 US disclosed
EP-3583100-B1 COMPOUNDS CONTAINING SI ATOMS FOR OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2021-05-05 EP disclosed
EP-3583102-B1 HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2020-11-04 EP disclosed
EP-3583101-B1 BIS-COMPOUNDS FOR OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2020-10-28 EP disclosed
EP-1933622-A2 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF Renovis, Inc. (US) 2008-06-25 EP disclosed
WO-2007109192-A2 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF RENOVIS, INC. (US) 2007-09-27 WO disclosed
US-20070225324-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof SECOND GENOME, INC. 2007-09-27 US disclosed
US-20070015817-A1 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith MCKIE JEFFREY A 2007-01-18 US disclosed
US-20070015817-A1 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith MCKIE JEFFREY A 2007-01-18 US disclosed
US-20070015817-A1 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith MCKIE JEFFREY A 2007-01-18 US disclosed
EP-1497277-A1 BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Signal Pharmaceuticals, Inc. (US) 2005-01-19 EP disclosed
US-20040092572-A1 Benzopyranone compounds, compositions thereof, and methods of treatment therewith NOVARTIS AG (CH) 2004-05-13 US disclosed
WO-2003089422-A1 BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, INC. (US) 2003-10-30 WO disclosed
US-6620838-B1 Anticarcinogenic, antimestasis, and antiarthritic agents; osteoporosis and endometriosis treatment SIGNAL PHARMACEUTICALS, INC. 2003-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210363122-A1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES PDE6C, ALDH1A2, PDE6A POLQ 707/4885P2RX7 281/4885KEAP1 272/4885
US-11702396-B2 Hydrophobic compounds for optically active devices UACA, CRYZ, TRPA1 POLQ 1191/4885P2RX7 1686/4885KEAP1 291/4885
US-20070225324-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof P2RX7, P2RX3, P2RX2 POLQ 4130/4885P2RX7 1/4885KEAP1 1016/4885
US-11040990-B2 Compounds containing Si atoms for optically active devices UACA, EYA3, PDE6C POLQ 68/4885P2RX7 1700/4885KEAP1 1798/4885
US-20070015817-A1 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith ESR2, CYP19A1, ESRRA POLQ 2657/4885P2RX7 3014/4885KEAP1 827/4885
US-11078177-B2 Compounds for optically active devices PDE6C, ALDH1A2, PDE6A POLQ 707/4885P2RX7 281/4885KEAP1 272/4885
US-11001576-B2 Compounds for optically active devices PDE6C, PDE6A, PDE6D POLQ 433/4885P2RX7 152/4885KEAP1 307/4885
US-20040092572-A1 Benzopyranone compounds, compositions thereof, and methods of treatment therewith ESR2, ESRRA, ESR1 POLQ 1895/4885P2RX7 3932/4885KEAP1 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.